Verapamil (versus unexposed)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17162
R71977		 Vaclavik - Verapamil, 2024 Preterm delivery during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.95 [1.13;3.34] -/15   -/71,860 - 15
ref
S13992
R54952		 Weber-Schoendorfer, 2008 Preterm children (<37 weeks) at least 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 4.01 [1.98;8.11] C 12/55   47/722 59 55
ref
Total 2 studies 2.69 [1.34;5.44] 59 70
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik - Verapamil, 2024Vaclavik - Verapamil, 2024 1.95[1.13; 3.34]-1555%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Weber-Schoendorfer, 2008Weber-Schoendorfer, 2008 4.01[1.98; 8.11]595545%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 60% 2.69[1.34; 5.44]59700.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.69[1.34; 5.44]597060%NAVaclavik - Verapamil, 2024 Weber-Schoendorfer, 2008 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.69[1.34; 5.44]597060%NAVaclavik - Verapamil, 2024 Weber-Schoendorfer, 2008 2 Tags Adjustment   - No  - No 2.69[1.34; 5.44]597060%NAVaclavik - Verapamil, 2024 Weber-Schoendorfer, 2008 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.69[1.34; 5.44]597060%NAVaclavik - Verapamil, 2024 Weber-Schoendorfer, 2008 2 All studiesAll studies 2.69[1.34; 5.44]597060%NAVaclavik - Verapamil, 2024 Weber-Schoendorfer, 2008 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.69[1.34; 5.44]597060%NAVaclavik - Verapamil, 2024 Weber-Schoendorfer, 2008 20.510.01.0